These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 8066630

  • 1. OKT3 for steroid-resistant renal allograft rejection: differential response in adults and children.
    Shmueli D, Nakache R, Lustig S, Bar Nathan N, Yussim A, Shaharabani E, Geier A, Shapira Z.
    Transplant Proc; 1994 Aug; 26(4):1948-9. PubMed ID: 8066630
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO, Feehally J, Scriven SD, Veitch PS, Bell PR.
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract] [Full Text] [Related]

  • 3. Late acute rejection in renal transplant recipients: response to steroid treatment.
    Prieto C, Pulido F, Rodríguez-Paternina E, Algranati C, Bello I, Farias J, G-Millet V.
    Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D, Bechstein WO, Blumhardt G, Lemmens P, Schattenfroh N, Neuhaus P.
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract] [Full Text] [Related]

  • 7. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
    Friend PJ, Rebello P, Oliveira D, Manna V, Cobbold SP, Hale G, Jamieson NV, Jamieson I, Calne RY, Harris DT.
    Transplant Proc; 1995 Feb; 27(1):869-70. PubMed ID: 7879212
    [No Abstract] [Full Text] [Related]

  • 8. Optimization of cyclosporine monotherapy--long-term graft function.
    Birkeland SA, Elbirk A, Rohr N, Jørgensen KA.
    Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
    [No Abstract] [Full Text] [Related]

  • 9. Misoprostol in renal transplantation.
    Curtis LD, Anwar N, Briggs JD, Buckels JA, Jones M, Karim MS, Koffman G, McGregor E, Neild G, Riad HN.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):602. PubMed ID: 8438432
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The high failure rate of OKT3 in the treatment of acute renal allograft rejection resistant to steroids with or without antithymocyte globulin.
    Davies SP, Brown EA, Woodrow DF, Phillips ME, Gower PE, Mee AD.
    Transplantation; 1991 Oct; 52(4):746-9. PubMed ID: 1926361
    [No Abstract] [Full Text] [Related]

  • 12. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES, Thistlethwaite JR, Haas M, Josephson MA, Newell KA, Bruce DS, Millis JM, Piper JB, Charette JI.
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract] [Full Text] [Related]

  • 13. Different trends in immunosuppression: 10 years' experience with cyclosporine after living related donor renal transplantation.
    Bakr MA, Sally S, Foda MA, Sobh MA, el-Sherif AK, Ghoneim MA.
    Transplant Proc; 1994 Dec; 26(6):3163-6. PubMed ID: 7998104
    [No Abstract] [Full Text] [Related]

  • 14. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N, Hong JH, DiBenedetto A, Clayton R, Miles AM, Markell MS, Distant DA, Fleishhacker J, Sommer BG.
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract] [Full Text] [Related]

  • 15. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
    Noël C, Hazzan M, Coppin MC, Pruvot FR, Bridoux F, Lelièvre G.
    Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
    [No Abstract] [Full Text] [Related]

  • 16. Role of cyclosporine rescue therapy in steroid resistant rejections.
    Sharma RK, Elhence R, Kher V, Gupta A, Kumar A, Bhandari M, Agrawal S.
    Transplant Proc; 1994 Oct; 26(5):2556-7. PubMed ID: 7940789
    [No Abstract] [Full Text] [Related]

  • 17. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF.
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract] [Full Text] [Related]

  • 18. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF, Venkat KK, Kupin W, Dumler F, Gracida C, Uniewski M, Anaise D, Tang DH.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract] [Full Text] [Related]

  • 19. Five-year experience with a triple drug protocol in renal transplantation.
    Pallardó LM, Sánchez J, García J, Puig N, Sánchez P, Górriz JL, Cruz JM.
    Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M, Latter DA, Loertscher R.
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.